Uganda & Serum Institute of India

Uganda: Uganda has reported cases of the Bundibugyo strain of Ebola, making it a focus for the World Health Organization's efforts to implement clinical trials for experimental treatments and vaccines.

Serum Institute of India: The Serum Institute of India collaborated with the University of Oxford to develop ChAdOx1 Bundibugyo, a vaccine candidate for the Ebola Bundibugyo strain.

Uganda: Neighboring country that experienced cases and deaths, declared free of the virus last month. At risk of renewed spread, impacting its health system and economy.

Serum Institute of India: Manufactured 620,000 doses of the Oxford vaccine candidate, positioning itself for large-scale production if trials succeed.

Uganda: Neighboring country that contained its linked outbreak, declaring itself Ebola-free. Its success provides a model for containment but remains at risk of cross-border spread.

Serum Institute of India: Manufactured a stockpile of 620,000 doses of the Oxford vaccine candidate. Its manufacturing capacity is crucial for potential large-scale deployment.

Uganda: Uganda>>> has reported confirmed Ebola cases linked to the outbreak in the Democratic Republic of the Congo>>>, leading to border closures and heightened surveillance efforts, while also expressing concern over the Uganda — Bundibugyo virus being named after one of its districts.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.

Uganda: Uganda has confirmed nine cases of Ebola Bundibugyo, including one death, indicating the regional spread of the outbreak.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.

Uganda: Uganda is affected by the Ebola outbreak as cases have spread across its border from the Democratic Republic of the Congo, increasing the risk of wider regional transmission.

Serum Institute of India: The Serum Institute of India is fast-tracking the development and production of a vaccine candidate targeting the Bundibugyo strain of Ebola, in collaboration with the University of Oxford and CEPI, to address the lack of an approved vaccine for this variant.